Clinical Trials for Clinicians | Linear Clinical Research

Find Clinical Trials for Your Patients

For clinicians, connect eligible patients to clinical trials in Australia and collaborate with one of the country's most trusted clinical research centres. At Linear, we make it easy for healthcare professionals to refer patients, access study details, and contribute to medical innovation through early and late-phase medical trials.

Become a Principal Investigator

Trials Currently Running at Linear

Linear partners with leading oncology research networks to deliver clinical trials across a broad range of cancers. Our Australia clinical research teams specialise in early and late-phase studies, offering streamlined trial access, rapid ethics approval, and end-to-end investigator support, ensuring both patient safety and research excellence.

Patient Referral Form

Non-Hodgkin Lymphoma

GCT3013-02

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

BGB-11417-101

A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

80948543LYM1001

A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

BGB-16673-101

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Waldenström Macroglobulinemia

BGB-11417-203

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

Non-Hodgkin Lymphoma

IKS03-01

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03, a CD19-Targeting Antibody Drug Conjugate (ADC), in Patients with Advanced B cell Non-Hodgkin Lymphomas (NHL)

Non-Hodgkin Lymphoma

87801493LYM1001

A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

BGB-21447-101

A Phase 1 Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

DZ2022B0002

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

DR-0201-ONC-001

A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Hodgkins Lymphoma

D9971C00001

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies

Multiple Myeloma

218670 (DREAMM20)

A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma

Advanced Solid Tumours

AN8025S0101

A Phase I Open-label Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of AN8025 in Participants with Unresectable Advanced or Metastatic Solid Tumors

Advanced Solid Tumours

BG-89894-101

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors

Advanced Solid Tumours

MOMA-341-001

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

OKN-4395-121

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

Advanced Ovarian Cancer

TORL123-002

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Advanced Solid Tumors

SNV4818-101

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumours

ADCE-T02-001

First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Metastatic Castration-Resistant Prostate Cancer

HRS-5041-103

A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Advanced Solid Tumours

AP402-101

A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients with Locally or Advanced Solid Tumors

HR+/ HER2- Metastatic Breast Cancer

BGB-21447-102

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

KRAS G12C Mutant Non-Small Cell Lung Cancer

TBBO8520-101

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer – The ONKORAS-101 Study

KRAS G12C Mutant Advanced Solid Tumours

FMC-376-CL101

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumours

VVD-159642-01

A Phase 1/1b, Open-label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Advanced Solid Tumours

GO43860

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

KRAS G12C-Mutant Advanced Solid Tumours

LOXO RAS-20001

A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Advanced Solid Tumours

BGB-A317-26808-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Advanced Squamous Non Small Cell Lung Cancer

HMBD-001-103

A Phase 1b study to evaluate HMBD-001 in combination with docetaxel with or without cetuximab in participants with advanced squamous non small cell lung cancer

Solid Tumors Harboring a TP53 Y220C Mutation

PMV-586-101

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Metastatic Triple-Negative Breast Cancer

CO42867

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)

Metastatic Triple-Negative Breast Cancer

PSMA-007-001

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Advanced Solid Tumours

AXA-042-FIH-01

A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors

Advanced Solid Tumours

IOS-1002-201

A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Advanced Solid Tumours

BGB-A317-A3055-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

HER2 Expressing Advanced Solid Tumours

IKS014-01

An open-label, single-arm, Phase 1a/1b study with a 3+3 dose escalation phase, which evaluates FS-1502 (IKS014) in patients with HER2 expressing advanced solid tumors (Phase 1a) followed by an expansion cohort (EC) in HER2+ breast cancer (BCa) (Phase 1b)

KRAS G12D-Mutant Advanced Solid Tumours

INCB 161734-101

A phase 1, open-label, multicenter study of INCB161734 in participants with advanced or metastatic solid tumours with KRAS G12D mutation

Selected HER2 Expressing Tumours

DESTINY-PanTumor02

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

BRAF and/or NRAS Mutation-positive Solid Tumours

KN-8701

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors

Advanced Solid Tumours

D6900C00001

A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies

Advanced Solid Tumours

DCSZ11-101

A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors

Advanced Solid Tumours

DB-1311-O-1001

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

Advanced or Metastatic Epithelial Tumours

MTX-TROP2-302

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Mutant NF2 or mNF2 Advanced Solid Tumours

VT3989-001

Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients with Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2)

Advanced Solid Tumours

GSK217228

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumours with MAPK Pathway Mutations

D3S-002-100

A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects with Advanced Solid Tumors with MAPK Pathway Mutations

Advanced Solid Tumors with a KRAS p.G12C Mutation

D3S-001-100

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation

Advanced Solid Tumours

BG-C9074-101

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumours with MTAP Deletion

BGB-58067-101

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5

Advanced Solid Tumours GPC3-Expressing Cancers

MTX-GPC3-303

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma

Advanced Solid Tumours

PTT-4256-01

A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Cancer to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTT-4256

Advanced Solid Tumours

BG-T187-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Advanced Solid Tumours

AMT-676-01

First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

Advanced Solid Tumours with KRAS Mutation or Amplification

BGB-53038-101

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Solid Tumours

SNV1521-101

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer

ZN-C3-002

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer

Advanced PRAME Positive Cancers

IMC-P115C-1005

A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination with Standard of Care Agents in HLA-A*02:01 Positive Participants with Advanced PRAME Positive Cancers

Advanced Solid Tumours with a SMARCA4

PRT7732-01

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4

Advanced Solid Tumours

DB-1419-O-1001

A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1419 in Subjects with Advanced/Metastatic Solid Tumors

Advanced Solid Tumours with AKT1 E17K Mutation

2618-001

AKTive-001: a Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation

Ovarian, Endometrial, NSCLC

ZWI-ZW191-101

A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants with Advanced Solid Tumors

Advanced Urothelial Carcinoma or Other Solid Tumours

LOXO-LNC-24001

A Phase 1a/1b Study of LY4052031, a Nectin-4-targeted ADC, in Patients with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Partnering in Clinical Research

As Australia's leading clinical research centre, Linear supports oncology specialists and investigators through every stage of the clinical trials process. We provide streamlined study set-up, access to experienced coordinators, and robust safety oversight, helping clinicians expand treatment options for their patients while contributing to Australia clinical research leadership.

Latest News

Stay informed with updates from Linear Clinical Research, including insights into Australian clinical trials, medical innovations, and stories from our research community.

Uncategorized

04 November, 2025

FAQs

Research

04 November, 2025

Before you attend your screening appointment

Thank You

04 November, 2025

Thank you for your interest

Clinicians Frequently asked questions

Why should I refer my patient to a clinical trial?

Clinical trials offer access to innovative therapies that may not be available through standard care. Referring patients can improve outcomes, provide additional monitoring, and contribute to the advancement of medical science. They give patients the opportunity to receive advanced treatments that could become the next standard of care, not only when other options have failed but also when early access may offer meaningful benefits.

Will I lose my patient if I refer them to a trial?

No. You remain your patient’s primary clinician. We respect the trust you’ve built and work collaboratively with you to ensure your patient receives the best possible care under your guidance. Our team will keep you informed of the patient’s progress and refer them back to you once they complete or withdraw from the trial.

How do I find suitable trials for my patients?

Linear is Western Australia’s leading provider of cancer clinical trials. To find trials that are currently recruiting patients, browse our active clinical trials above. If you are looking for an oncology solid tumour trial, you can also search the Cancer Trials WA database: https://cancertrialswa.zepli.com.au/ If you need assistance identifying a suitable trial for a specific patient, please contact (https://www.linear.org.au/contact-us/) our team and we can help guide you to relevant recruitment opportunities.

What are the eligibility criteria for trials?

Each trial has specific inclusion/exclusion criteria based on disease stage, and clinical status. These are designed to ensure patient safety and data integrity.

What are the benefits of a clinical trial for my patient?

Patients taking part in a clinical trial often benefit from a greater degree of clinical oversight and monitoring of their disease by their healthcare team, for example more frequent visits and more thorough assessments of their disease status. Advances in trial design and targeted therapies mean that patients sometimes experience benefits beyond those traditionally seen in early-phase research.

For some patients who are perhaps unable to access alternative treatment options, or where existing medicines have failed to provide benefit, clinical trials can enable earlier access to new, innovative medicines. Additionally, supporting clinical trials helps progress scientific understanding of medicine and improves healthcare options for future generations across the globe.

Join Our Network of Clinicians

Partner with Linear to connect your patients to cutting-edge medical trials and emerging therapies.  Together, we can advance evidence-based medicine and improve outcomes for people across Western Australia and beyond.